$CLNN
Clene Inc. Stock $clnn

$clnn Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000143774924007542 Filed on March 13, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$73.00K	$170.0K	$654.0K
YoY Change	-31.78%	-27.35%	38.27%
Cost Of Revenue	$16.00K	$38.00K	$121.0K
YoY Change	220.0%	442.86%	365.38%
Gross Profit	$57.00K	$132.0K	$533.0K
YoY Change	-44.12%	-41.85%	19.24%
Gross Profit Margin	78.08%	77.65%	81.5%
Selling, General & Admin	$3.354M	$3.322M	$14.15M
YoY Change	-0.53%	-18.24%	-15.3%
% of Gross Profit	5884.21%	2516.67%	2654.97%
Research & Development	$5.869M	$6.318M	$25.22M
YoY Change	-20.64%	-16.13%	-21.0%
% of Gross Profit	10296.49%	4786.36%	4731.14%
Depreciation & Amortization	$420.0K	$422.0K	$1.705M
YoY Change	4.48%	38.82%	67.32%
% of Gross Profit	736.84%	319.7%	319.89%
Operating Expenses	$5.869M	$10.06M	$41.07M
YoY Change	-20.64%	-15.45%	28.67%
Operating Profit	-$9.200M	-$9.930M	-$40.54M
YoY Change	-14.28%	-14.93%	-16.26%
Interest Expense	$1.244M	-$667.0K	-$1.313M
YoY Change	16.7%	-108.07%	-110.47%
% of Operating Profit
Other Income/Expense, Net	-$1.848M	$424.0K	-$7.651M
YoY Change	78.03%	-81.97%	-141.38%
Pretax Income	-$11.08M	-$10.17M	-$49.50M
YoY Change	-5.86%	865.18%	65.47%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$11.08M	-$10.17M	-$49.50M
YoY Change	-5.86%	865.18%	65.47%
Net Earnings / Revenue	-15178.08%	-5984.12%	-7569.42%
Basic Earnings Per Share	-$0.09		-$0.47
Diluted Earnings Per Share	-$0.09	-$0.08	-$0.47
COMMON SHARES
Basic Shares Outstanding	128.4M	128.4M	104.9M
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$27.91M	$35.00M	$35.00M
YoY Change	51.34%	50.12%	50.12%
Cash & Equivalents	$21.73M	$28.82M
Short-Term Investments	$6.178M	$6.179M	$6.179M
Other Short-Term Assets	$832.0K	$2.477M	$2.477M
YoY Change	-13.51%	326.33%	-13.72%
Inventory	$37.00K	$37.00K	$37.00K
Prepaid Expenses
Receivables	$64.00K	$143.0K	$143.0K
Other Receivables	$1.442M	$1.195M	$1.195M
Total Short-Term Assets	$32.11M	$38.85M	$38.85M
YoY Change	29.37%	33.08%	33.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.90M	$13.43M	$13.43M
YoY Change	-14.05%	-11.87%	-11.87%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$58.00K	$58.00K	$58.00K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$12.96M	$13.49M	$13.49M
YoY Change	-13.99%	-11.83%	-11.83%
TOTAL ASSETS
Total Short-Term Assets	$32.11M	$38.85M	$38.85M
Total Long-Term Assets	$12.96M	$13.49M	$13.49M
Total Assets	$45.07M	$52.34M	$52.34M
YoY Change	12.99%	17.64%	17.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.645M	$1.504M	$1.504M
YoY Change	170.56%	-50.1%	-50.1%
Accrued Expenses	$3.905M	$4.296M	$4.296M
YoY Change	-34.18%	11.21%	-1.26%
Deferred Revenue
YoY Change
Short-Term Debt	$5.042M	$4.876M	$4.876M
YoY Change
Long-Term Debt Due	$14.99M	$14.65M	$14.65M
YoY Change	52.58%	125.72%	125.72%
Total Short-Term Liabilities	$26.19M	$25.33M	$25.33M
YoY Change	55.16%	82.8%	82.8%
LONG-TERM LIABILITIES
Long-Term Debt	$7.085M	$7.152M	$7.152M
YoY Change	-57.38%	-62.92%	-62.92%
Other Long-Term Liabilities	$7.535M	$6.469M	$6.469M
YoY Change	-6.0%	-20.25%	-20.25%
Total Long-Term Liabilities	$14.62M	$13.62M	$13.62M
YoY Change	-40.66%	-50.29%	-50.29%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.19M	$25.33M	$25.33M
Total Long-Term Liabilities	$14.62M	$13.62M	$13.62M
Total Liabilities	$40.81M	$38.95M	$38.95M
YoY Change	-1.71%	-5.59%	-5.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$253.8M	-$242.7M
YoY Change	23.8%	25.62%
Common Stock	$13.00K	$13.00K
YoY Change	62.5%	85.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.264M	$13.39M	$13.39M
YoY Change
Total Liabilities & Shareholders Equity	$45.07M	$52.34M	$52.34M
YoY Change	12.99%	17.64%	17.64%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$11.08M	-$10.17M	-$49.50M
YoY Change	-5.86%	865.18%	65.47%
Depreciation, Depletion And Amortization	$420.0K	$422.0K	$1.705M
YoY Change	4.48%	38.82%	67.32%
Cash From Operating Activities	-$7.100M	-$7.172M	-$30.17M
YoY Change	-22.83%	-7.05%	-22.64%
INVESTING ACTIVITIES
Capital Expenditures	$11.00K	$43.00K	$330.0K
YoY Change	-96.04%	-97.47%	-93.63%
Acquisitions
YoY Change
Other Investing Activities	$82.00K	-$6.169M	-$1.169M
YoY Change	-98.36%	-254.88%	-76.55%
Cash From Investing Activities	$71.00K	-$6.212M	-$1.499M
YoY Change	-98.5%	-372.22%	-85.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$42.09M
YoY Change			267.31%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$19.00K	-18.00K	42.16M
YoY Change	-100.41%	-100.11%	144.44%
NET CHANGE
Cash From Operating Activities	-$7.100M	-7.172M	-30.17M
Cash From Investing Activities	$71.00K	-6.212M	-1.499M
Cash From Financing Activities	-$19.00K	-18.00K	42.16M
Net Change In Cash	-$7.089M	-13.40M	10.49M
YoY Change	-6544.55%	-222.5%	-132.84%
FREE CASH FLOW
Cash From Operating Activities	-$7.100M	-$7.172M	-$30.17M
Capital Expenditures	$11.00K	$43.00K	$330.0K
Free Cash Flow	-$7.111M	-$7.215M	-$30.50M
YoY Change	-24.97%	-23.38%	-30.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	128422851
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	128422851
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74759591
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74759591
CY2023	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2022	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	usd
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	112000	usd
CY2023	us-gaap	Lease Cost LeaseCost	1399000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2023	us-gaap	Open Tax Year OpenTaxYear	2016 2017 2018 2019 2020 2021 2022 2023
CY2023	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	01-39834
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-2828339
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	6550 South Millrock Drive, Suite G50
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Salt Lake City
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	UT
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	84121
CY2023	dei	City Area Code CityAreaCode	801
CY2023	dei	Local Phone Number LocalPhoneNumber	676-9695
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	78100000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	128430098
CY2023	dei	Auditor Firm AuditorFirmId	34
CY2023	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2023	dei	Auditor Location AuditorLocation	Salt Lake City, UT
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28821000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18332000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	6179000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	4983000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	143000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	189000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	37000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	43000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3672000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5648000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	38852000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	29195000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	58000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	58000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4168000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4602000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	9263000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	10638000	usd
CY2023Q4	us-gaap	Assets Assets	52341000	usd
CY2022Q4	us-gaap	Assets Assets	44493000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1504000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3014000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3720000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3863000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	576000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	488000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	27000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	74000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	14627000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	6418000	usd
CY2023Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	4876000	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25330000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13857000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4903000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5557000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	34000	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	1894000	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	9483000	usd
CY2023Q4	clnn	Convertible Note Payable Noncurrent ConvertibleNotePayableNoncurrent	5258000	usd
CY2022Q4	clnn	Convertible Note Payable Noncurrent ConvertibleNotePayableNoncurrent	9770000	usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1481000	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	usd
CY2023Q4	clnn	Clene Nanomedicine Contingent Earnout CleneNanomedicineContingentEarnout	75000	usd
CY2022Q4	clnn	Clene Nanomedicine Contingent Earnout CleneNanomedicineContingentEarnout	2264000	usd
CY2023Q4	clnn	Initial Shareholders Contingent Earnout InitialShareholdersContingentEarnout	10000	usd
CY2022Q4	clnn	Initial Shareholders Contingent Earnout InitialShareholdersContingentEarnout	291000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	38951000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	41256000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	13000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	7000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	255901000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	196246000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-242723000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-193219000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	199000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	203000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	13390000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3237000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	52341000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44493000	usd
CY2023	us-gaap	Revenues Revenues	654000	usd
CY2022	us-gaap	Revenues Revenues	473000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	121000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	26000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26655000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31920000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14418000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16936000	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	41194000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	48882000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-40540000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-48409000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	1389000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	225000	usd
CY2023	us-gaap	Interest Expense InterestExpense	4558000	usd
CY2022	us-gaap	Interest Expense InterestExpense	3296000	usd
CY2023	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	usd
CY2022	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	420000	usd
CY2023	clnn	Purchase Agreement Commitment Share Expense PurchaseAgreementCommitmentShareExpense	402000	usd
CY2022	clnn	Purchase Agreement Commitment Share Expense PurchaseAgreementCommitmentShareExpense	-0	usd
CY2023	clnn	Issuance Costs For Common Stock Warrant Liability IssuanceCostsForCommonStockWarrantLiability	333000	usd
CY2022	clnn	Issuance Costs For Common Stock Warrant Liability IssuanceCostsForCommonStockWarrantLiability	-0	usd
CY2023	clnn	Gain Loss On Issuance Of Equity GainLossOnIssuanceOfEquity	-14840000	usd
CY2022	clnn	Gain Loss On Issuance Of Equity GainLossOnIssuanceOfEquity	0	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-6337000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-169000	usd
CY2023	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	2189000	usd
CY2022	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	15836000	usd
CY2023	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	281000	usd
CY2022	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	2026000	usd
CY2023	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	963000	usd
CY2022	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	3079000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	32000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8964000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	18491000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-49504000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29918000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-49504000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-29918000	usd
CY2023	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	16000	usd
CY2022	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-14000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-20000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-16000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-30000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-49508000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29948000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.47
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104938819
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	65204663
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	12597000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11460000	usd
CY2022	clnn	Reclassification Of Common Stock Warrant Liability To Permanent Equity ReclassificationOfCommonStockWarrantLiabilityToPermanentEquity	305000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	310000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8513000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-14000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-16000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-29918000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3237000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	45574000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	4970000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9117000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	16000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-20000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-49504000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	13390000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-49504000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-29918000	usd
CY2023	us-gaap	Depreciation Depreciation	1705000	usd
CY2022	us-gaap	Depreciation Depreciation	1019000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	434000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	389000	usd
CY2023	clnn	Purchase Agreement Commitment Share Expense PurchaseAgreementCommitmentShareExpense	402000	usd
CY2022	clnn	Purchase Agreement Commitment Share Expense PurchaseAgreementCommitmentShareExpense	0	usd
CY2023	clnn	Issuance Costs For Common Stock Warrant Liability IssuanceCostsForCommonStockWarrantLiability	333000	usd
CY2022	clnn	Issuance Costs For Common Stock Warrant Liability IssuanceCostsForCommonStockWarrantLiability	0	usd
CY2023	clnn	Gain Loss On Issuance Of Equity GainLossOnIssuanceOfEquity	-14840000	usd
CY2022	clnn	Gain Loss On Issuance Of Equity GainLossOnIssuanceOfEquity	-0	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-6337000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-169000	usd
CY2023	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	2189000	usd
CY2022	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	15836000	usd
CY2023	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	281000	usd
CY2022	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	2026000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	9117000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	8513000	usd
CY2023	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	-0	usd
CY2022	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	420000	usd
CY2023	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	-0	usd
CY2022	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	-2000	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1150000	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	863000	usd
CY2023	clnn	Non Cash Interest Income Expense NonCashInterestIncomeExpense	-350000	usd
CY2022	clnn	Non Cash Interest Income Expense NonCashInterestIncomeExpense	-112000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-46000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	140000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-6000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1976000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1443000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1510000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	285000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-143000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	253000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-566000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-493000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30171000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39011000	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	6169000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	24614000	usd
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	5000000	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	12015000	usd
CY2023	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	7614000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	330000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5179000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1499000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10164000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	310000	usd
CY2023	clnn	Proceeds From Issuance Of Common Stock And Warrants Net Of Offering Costs ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts	42094000	usd
CY2022	clnn	Proceeds From Issuance Of Common Stock And Warrants Net Of Offering Costs ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts	11460000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	81000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	135000	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	350000	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	5695000	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	-0	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	81000	usd
CY2023	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts	200000	usd
CY2022	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts	-0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	42163000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17249000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-4000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-30000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10489000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-31956000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18390000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	50346000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	28879000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18390000	usd
CY2023Q4	us-gaap	Cash Cash	28821000	usd
CY2022Q4	us-gaap	Cash Cash	18332000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	58000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	58000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28879000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18390000	usd
CY2023	clnn	Common Stock Warrant Liability Recorded Upon Debt Modification CommonStockWarrantLiabilityRecordedUponDebtModification	692000	usd
CY2022	clnn	Common Stock Warrant Liability Recorded Upon Debt Modification CommonStockWarrantLiabilityRecordedUponDebtModification	0	usd
CY2023	clnn	Common Stock Warrant Liability Recorded Upon Public Stock Offering CommonStockWarrantLiabilityRecordedUponPublicStockOffering	7126000	usd
CY2022	clnn	Common Stock Warrant Liability Recorded Upon Public Stock Offering CommonStockWarrantLiabilityRecordedUponPublicStockOffering	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2343000	usd
CY2023	clnn	Lease Incentive Realized LeaseIncentiveRealized	0	usd
CY2022	clnn	Lease Incentive Realized LeaseIncentiveRealized	500000	usd
CY2023	clnn	Lease Liability Settled Through Termination Of Lease LeaseLiabilitySettledThroughTerminationOfLease	0	usd
CY2022	clnn	Lease Liability Settled Through Termination Of Lease LeaseLiabilitySettledThroughTerminationOfLease	602000	usd
CY2023	clnn	Reclassification Of Common Stock Warrant Liability To Permanent Equity ReclassificationOfCommonStockWarrantLiabilityToPermanentEquity	0	usd
CY2022	clnn	Reclassification Of Common Stock Warrant Liability To Permanent Equity ReclassificationOfCommonStockWarrantLiabilityToPermanentEquity	305000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	806000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	3059000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	2320000	usd
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-40500000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-48400000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-242700000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-193200000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	35000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	23300000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30200000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39000000	usd
CY2023	clnn	Minimum Cash Balance For Loan Covenant MinimumCashBalanceForLoanCovenant	5000000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and disclosure of contingent assets and liabilities, and the reported amounts of expenses. We base our estimates on historical experience and various other assumptions that we believe to be reasonable. Actual results <em style="font: inherit;"> may </em>differ from those estimates or assumptions. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience, and any changes in estimates will be recorded in future periods as they develop.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"> </p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Concentrations of Credit Risk</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">Financial instruments which potentially subject us to significant concentrations of credit risk consist primarily of cash. Our cash is held in financial institutions and amounts on deposit <em style="font: inherit;"> may </em>at times exceed federally insured limits. We have <em style="font: inherit;">not</em> experienced any losses on our deposits of cash and do <em style="font: inherit;">not</em> believe that we are subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"> </p>
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	23000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	14000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	29000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	14000	usd
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	5000000	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	12015000	usd
CY2023	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	7614000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	5000000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	19629000	usd
CY2023Q4	us-gaap	Government Assistance Amount Cumulative GovernmentAssistanceAmountCumulative	1195000	usd
CY2022Q4	us-gaap	Government Assistance Amount Cumulative GovernmentAssistanceAmountCumulative	2777000	usd
CY2023Q4	us-gaap	Supplies Supplies	1909000	usd
CY2022Q4	us-gaap	Supplies Supplies	2290000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	568000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	581000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3672000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5648000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	16150000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	15911000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	6887000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	5273000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	9263000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	10638000	usd
CY2023	us-gaap	Depreciation Depreciation	1705000	usd
CY2022	us-gaap	Depreciation Depreciation	1019000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	2120000	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	2007000	usd
CY2023Q4	clnn	Accrued Cro And Clinical Fees AccruedCroAndClinicalFees	481000	usd
CY2022Q4	clnn	Accrued Cro And Clinical Fees AccruedCroAndClinicalFees	1297000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1119000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	559000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3720000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3863000	usd
CY2023Q4	clnn	Number Of Real Estate Leases NumberOfRealEstateLeases	3	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.096	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.096	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y4M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y3M18D
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	636000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	636000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	449000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	326000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	187000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	310000	usd
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.11	pure
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.102	pure
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y4M24D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y2M12D
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	27000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1082000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1208000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1236000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1132000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1093000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1694000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	27000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	7445000	usd
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	-0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1966000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	27000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5479000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	27000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	576000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4903000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	82000	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	11000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	16000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	1011000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	948000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	3000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	262000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	304000	usd
CY2022	us-gaap	Lease Cost LeaseCost	1351000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1276000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1253000	usd
CY2023	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	11000	usd
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	16000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	81000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	135000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	16915000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	16488000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-48578000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-26941000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-926000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2977000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-49504000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29918000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-10383000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6282000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1402000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-320000	usd
CY2023	clnn	Effective Income Tax Rate Reconciliation Gain Loss On Initial Issuance Of Equity Amount EffectiveIncomeTaxRateReconciliationGainLossOnInitialIssuanceOfEquityAmount	-3186000	usd
CY2022	clnn	Effective Income Tax Rate Reconciliation Gain Loss On Initial Issuance Of Equity Amount EffectiveIncomeTaxRateReconciliationGainLossOnInitialIssuanceOfEquityAmount	-0	usd
CY2023	clnn	Effective Income Tax Rate Reconciliation Change In Fair Value Of Derivative EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivative	-1331000	usd
CY2022	clnn	Effective Income Tax Rate Reconciliation Change In Fair Value Of Derivative EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivative	-36000	usd
CY2023	clnn	Effective Income Tax Rate Reconciliation Change In Fair Value Of Derivative Contingent Earnout EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeContingentEarnout	-519000	usd
CY2022	clnn	Effective Income Tax Rate Reconciliation Change In Fair Value Of Derivative Contingent Earnout EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeContingentEarnout	-3029000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	982000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	423000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	431000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	-170000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-80000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-261000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-1277000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-266000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	67000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	12623000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	10454000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	35246000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	30460000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1281000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1131000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	5538000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3808000	usd
CY2023Q4	clnn	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	1335000	usd
CY2022Q4	clnn	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	1312000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1016000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	999000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	8424000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	4712000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6037000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3849000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	510000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	396000	usd
CY2023Q4	clnn	Deferred Tax Assets Liabilities Other DeferredTaxAssetsLiabilitiesOther	-40000	usd
CY2022Q4	clnn	Deferred Tax Assets Liabilities Other DeferredTaxAssetsLiabilitiesOther	20000	usd
CY2023Q4	clnn	Deferred Tax Assets Liability Gross DeferredTaxAssetsLiabilityGross	57315000	usd
CY2022Q4	clnn	Deferred Tax Assets Liability Gross DeferredTaxAssetsLiabilityGross	44689000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	57315000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	44689000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	-0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	-0	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9117000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8513000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9117000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8513000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15260297
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.98
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M10D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2348000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7053200
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.92
CY2023	clnn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm	P9Y5M19D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	467109
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.45
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21846388
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.26
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M10D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	302000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	11717679
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.58
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y10M2D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	302000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	21846388
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	2.26
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y3M10D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	302000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.73
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.49
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	43479
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.15
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	32609
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	1.15
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	11000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P0Y2M23D
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	0	usd
CY2023Q4	clnn	Clene Nanomedicine Contingent Earnout Fair Value Disclosure CleneNanomedicineContingentEarnoutFairValueDisclosure	75000	usd
CY2023Q4	clnn	Initial Shareholders Contingent Earnout Fair Value Disclosure InitialShareholdersContingentEarnoutFairValueDisclosure	10000	usd
CY2022Q4	clnn	Clene Nanomedicine Contingent Earnout Fair Value Disclosure CleneNanomedicineContingentEarnoutFairValueDisclosure	2264000	usd
CY2022Q4	clnn	Initial Shareholders Contingent Earnout Fair Value Disclosure InitialShareholdersContingentEarnoutFairValueDisclosure	291000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	128422851
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74759591
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	105432083
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4477045
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-49504000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-29918000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104938819
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	65204663
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.47
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	136382323
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28831518
CY2018Q3	clnn	Related Party Transaction Royalty Fee Rate For Revenues RelatedPartyTransactionRoyaltyFeeRateForRevenues	0.03	pure

Files In Submission

Name	View Source	Status
0001437749-24-007542-index-headers.html	Edgar Link	pending
0001437749-24-007542-index.html	Edgar Link	pending
0001437749-24-007542.txt	Edgar Link	pending
0001437749-24-007542-xbrl.zip	Edgar Link	pending
clnn-20231231.xsd	Edgar Link	pending
clnn20231231_10k.htm	Edgar Link	pending
ex_584128.htm	Edgar Link	pending
ex_584129.htm	Edgar Link	pending
ex_584130.htm	Edgar Link	pending
ex_584131.htm	Edgar Link	pending
ex_584132.htm	Edgar Link	pending
ex_584133.htm	Edgar Link	pending
ex_584134.htm	Edgar Link	pending
ex_625242.htm	Edgar Link	pending
figure1v3.jpg	Edgar Link	pending
figure2v2.jpg	Edgar Link	pending
figure3full.jpg	Edgar Link	pending
figure4v2.jpg	Edgar Link	pending
figure5av2.jpg	Edgar Link	pending
figure5bv3.jpg	Edgar Link	pending
figure6v3.jpg	Edgar Link	pending
figure8.jpg	Edgar Link	pending
figure9at35percent.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
newpipeline.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
clnn-20231231_def.xml	Edgar Link	unprocessable
clnn-20231231_lab.xml	Edgar Link	unprocessable
clnn-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
clnn20231231_10k_htm.xml	Edgar Link	completed
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
clnn-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLNN
Clene Inc. Stock $clnn

2024 Q1 Form 10-K Financial Statement

#000143774924007542 Filed on March 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLNN Clene Inc. Stock $clnn

2024 Q1 Form 10-K Financial Statement

#000143774924007542 Filed on March 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLNN
Clene Inc. Stock $clnn